Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Radioactive iodine therapy is often part of the standard treatment for Papillary Thyroid
Carcinoma (PTC) patients. However, in many patients, tumors develop a resistance or no longer
respond to radioactive iodine therapy (iodine-refractory). Several lines of evidence suggest
that blocking the BRAF gene may help to re-sensitize the tumors to radioactive iodine. BRAF
is a protein that plays a central role in the growth and survival of cancer cells in some
types of PTC. The investigational drug GSK2118436 may work by blocking the BRAF protein in
cancer cells lines and tumors that have a mutated BRAF gene.
In this research study, the investigators are looking to see if GSK2118436 can re-sensitize
iodine-refractory PTC to radioactive iodine therapy. The investigators are also looking at
the safety of adding GSK2118436 to radioactive iodine therapy.